Abstract
We appreciate the comments made on our review paper focused on possible predictive factors for responses to PD-1/PD-L1 checkpoint inhibitors in the field of hepatocellular carcinoma [...].
Highlights
We appreciate the comments made on our review paper focused on possible predictive factors for responses to PD-1/PD-L1 checkpoint inhibitors in the field of hepatocellular carcinoma [1]
We fully agree that the statement “Certainly, high tumor mutational burden and neoantigen load have been noted to predict the response to immunotherapies, including anti-PD-1 therapy in melanoma, non-small-cell lung carcinoma” is not supported by the given reference of Topalian et al for the year 2012 [2]
As mentioned in the comment, the correct reference is Goodman et al.’s work from 2017 [3], cited in our original review as reference number 60, where the authors demonstrated a linear correlation between higher tumor mutational burden and better outcome parameters based on 151 immunotherapy-treated patients
Summary
We completely agree that randomized controlled clinical trials are needed to determine the ability of tumor mutational burden to predict responses to PD-1/PD-L1 checkpoint inhibitors, mainly in different tumor types.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
